Astellas Pharma EMEA appoints Eugene Van Rensburg as Chief Financial Officer

Mittwoch, 16.09.2015 12:30 von PR Newswire - Aufrufe: 335

PR Newswire

CHERTSEY, England, September 16, 2015 /PRNewswire/ --

Astellas Pharma EMEA, the regional headquarters of Astellas Pharma Inc. for Europe, the Middle East and Africa, has appointed Eugene Van Rensburg to the position of Chief Financial Officer from his previous role as Senior Finance Director. Eugene succeeds Niek Stander, who will now head up the company's German operations as Managing Director of Astellas Pharma GmbH.

     (Logo: http://photos.prnewswire.com/prnh/20140522/689211 )

Astellas was founded in 2005 through the merger of Yamanouchi and Fujisawa to create an international pharmaceutical company, placing innovation for patients at its heart. Astellas is now the second-largest pharmaceutical company in Japan and among the top 20 globally. The EMEA region is an important territory for Astellas, contributing around one quarter of the company's global sales.  Despite continued austerity in Europe, FY2014 saw Astellas' sales in the EMEA region increase for the fourth consecutive year, by 14.8% to €2,258 million.

Astellas is dedicated to improving the health of people around the world by discovering and developing innovative, reliable medicines, particularly for challenging and serious conditions that are hard to treat. The company's vision is to be on the forefront of the latest medical discoveries and understanding, turning innovative science into valuable new therapy options for patients.

Ken Jones, President and CEO Astellas Pharma EMEA, commented:

"In the ten years since Astellas was formed the company has grown strongly and developed ground-breaking medicines that are changing patients' lives. Eugene will play a major role as we work to sustain this success by maximising the value of our portfolio, prioritising research and development, and achieving operational excellence."  

As Chief Financial Officer, Eugene will oversee the Finance function across 40 countries in Europe, the Middle East and Africa, with responsibility for all financial planning and operations, as well as tax, treasury, procurement and information systems. As the company moves forward his main priority will be to focus on strategic planning and budgeting, cost and process optimisation, profitability analysis and innovative ways to maximise value of existing brands and assets.

Eugene Van Rensburg, new Chief Financial Officer at Astellas Pharma EMEA, commented:

"It is an exciting time to be a trusted advisor and part of the leadership team at Astellas. Our company is building on existing areas of excellence, such as our franchises in urology, oncology and transplantation, by proactively seeking novel technologies and new opportunities in different therapeutic areas. We've recently launched three new classes of treatment in the EMEA region, and with eight therapies in late stage development, Astellas has a unique platform for continued growth."

With over 15 years of diverse and international industry experience, tackling the financial challenges of high-growth organisations, Eugene has the expertise to enhance Astellas' operational efficiency and effectiveness as it undertakes strategic management of its expansion.

About Astellas Pharma Europe Ltd. 

Astellas Pharma Europe Ltd. operates in 40 countries across Europe, the Middle East and Africa, and is the EMEA regional business of Tokyo-based Astellas Pharma Inc. Astellas is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceuticals. The organisation's focus is to deliver outstanding R&D and marketing to continue growing in the world pharmaceutical market. Astellas' presence in Europe also includes an R&D site and three manufacturing plants. The company employs over 4,500 people across the EMEA region.

Mehr Nachrichten kostenlos abonnieren
E-Mail-Adresse
Ich möchte Benachrichtigungen von ARIVA.DE erhalten.
Ja, ich habe die Datenschutzhinweise gelesen und akzeptiert (Pflichtfeld).

Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.

Kurse

  
14,265
+2,11%
Astellas Pharma Chart
16,33 $
+1,94%
Astellas Pharma ADR Chart